Engineering cytokine therapeutics

Jeroen Deckers; Tom Anbergen; Ayla M. Hokke; Anne de Dreu; David P. Schrijver; Koen de Bruin; Yohana C. Toner; Thijs Beldman; Jamie B. Spangler; Tom F.A. de Greef; Francesca Grisoni; Roy van der Meel; Leo A.B. Joosten; Maarten Merkx; Mihai G. Netea; Willem J.M. Mulder

doi:10.1038/s44222-023-00030-y

Engineering cytokine therapeutics

Jeroen Deckers, Tom Anbergen, Ayla M. Hokke, Anne de Dreu, David P. Schrijver, Koen de Bruin, Yohana C. Toner, Thijs Beldman, Jamie B. Spangler, Tom F.A. de Greef, Francesca Grisoni, Roy van der Meel, Leo A.B. Joosten, Maarten Merkx, Mihai G. Netea (Corresponding author), Willem J.M. Mulder (Corresponding author)

Research output: Contribution to journal › Article › Academic › peer-review

98 Citations (Scopus)

161 Downloads (Pure)

Abstract

Cytokines have pivotal roles in immunity, making them attractive as therapeutics for a variety of immune-related disorders. However, the widespread clinical use of cytokines has been limited by their short blood half-lives and severe side effects caused by low specificity and unfavourable biodistribution. Innovations in bioengineering have aided in advancing our knowledge of cytokine biology and yielded new technologies for cytokine engineering. In this Review, we discuss how the development of bioanalytical methods, such as sequencing and high-resolution imaging combined with genetic techniques, have facilitated a better understanding of cytokine biology. We then present an overview of therapeutics arising from cytokine re-engineering, targeting and delivery, mRNA therapeutics and cell therapy. We also highlight the application of these strategies to adjust the immunological imbalance in different immune-mediated disorders, including cancer, infection and autoimmune diseases. Finally, we look ahead to the hurdles that must be overcome before cytokine therapeutics can live up to their full potential.

Original language	English
Article number	e206
Pages (from-to)	286-303
Number of pages	18
Journal	Nature Reviews. Bioengineering
Volume	1
Issue number	4
Early online date	16 Feb 2023
DOIs	https://doi.org/10.1038/s44222-023-00030-y
Publication status	Published - Apr 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s44222-023-00030-y

pdfFinal published version, 3.7 MBLicence: TAVERNE

Cite this

Deckers, J., Anbergen, T., Hokke, A. M., de Dreu, A., Schrijver, D. P., de Bruin, K., Toner, Y. C., Beldman, T., Spangler, J. B., de Greef, T. F. A., Grisoni, F., van der Meel, R., Joosten, L. A. B., Merkx, M., Netea, M. G., & Mulder, W. J. M. (2023). Engineering cytokine therapeutics. Nature Reviews. Bioengineering, 1(4), 286-303. Article e206. https://doi.org/10.1038/s44222-023-00030-y

@article{5786e6b6445942b58c3f6cdc6c405ea8,

title = "Engineering cytokine therapeutics",

abstract = "Cytokines have pivotal roles in immunity, making them attractive as therapeutics for a variety of immune-related disorders. However, the widespread clinical use of cytokines has been limited by their short blood half-lives and severe side effects caused by low specificity and unfavourable biodistribution. Innovations in bioengineering have aided in advancing our knowledge of cytokine biology and yielded new technologies for cytokine engineering. In this Review, we discuss how the development of bioanalytical methods, such as sequencing and high-resolution imaging combined with genetic techniques, have facilitated a better understanding of cytokine biology. We then present an overview of therapeutics arising from cytokine re-engineering, targeting and delivery, mRNA therapeutics and cell therapy. We also highlight the application of these strategies to adjust the immunological imbalance in different immune-mediated disorders, including cancer, infection and autoimmune diseases. Finally, we look ahead to the hurdles that must be overcome before cytokine therapeutics can live up to their full potential.",

author = "Jeroen Deckers and Tom Anbergen and Hokke, {Ayla M.} and {de Dreu}, Anne and Schrijver, {David P.} and {de Bruin}, Koen and Toner, {Yohana C.} and Thijs Beldman and Spangler, {Jamie B.} and {de Greef}, {Tom F.A.} and Francesca Grisoni and {van der Meel}, Roy and Joosten, {Leo A.B.} and Maarten Merkx and Netea, {Mihai G.} and Mulder, {Willem J.M.}",

year = "2023",

month = apr,

doi = "10.1038/s44222-023-00030-y",

language = "English",

volume = "1",

pages = "286--303",

journal = "Nature Reviews. Bioengineering",

issn = "2731-6092",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Engineering cytokine therapeutics

AU - Deckers, Jeroen

AU - Anbergen, Tom

AU - Hokke, Ayla M.

AU - de Dreu, Anne

AU - Schrijver, David P.

AU - de Bruin, Koen

AU - Toner, Yohana C.

AU - Beldman, Thijs

AU - Spangler, Jamie B.

AU - de Greef, Tom F.A.

AU - Grisoni, Francesca

AU - van der Meel, Roy

AU - Joosten, Leo A.B.

AU - Merkx, Maarten

AU - Netea, Mihai G.

AU - Mulder, Willem J.M.

PY - 2023/4

Y1 - 2023/4

N2 - Cytokines have pivotal roles in immunity, making them attractive as therapeutics for a variety of immune-related disorders. However, the widespread clinical use of cytokines has been limited by their short blood half-lives and severe side effects caused by low specificity and unfavourable biodistribution. Innovations in bioengineering have aided in advancing our knowledge of cytokine biology and yielded new technologies for cytokine engineering. In this Review, we discuss how the development of bioanalytical methods, such as sequencing and high-resolution imaging combined with genetic techniques, have facilitated a better understanding of cytokine biology. We then present an overview of therapeutics arising from cytokine re-engineering, targeting and delivery, mRNA therapeutics and cell therapy. We also highlight the application of these strategies to adjust the immunological imbalance in different immune-mediated disorders, including cancer, infection and autoimmune diseases. Finally, we look ahead to the hurdles that must be overcome before cytokine therapeutics can live up to their full potential.

AB - Cytokines have pivotal roles in immunity, making them attractive as therapeutics for a variety of immune-related disorders. However, the widespread clinical use of cytokines has been limited by their short blood half-lives and severe side effects caused by low specificity and unfavourable biodistribution. Innovations in bioengineering have aided in advancing our knowledge of cytokine biology and yielded new technologies for cytokine engineering. In this Review, we discuss how the development of bioanalytical methods, such as sequencing and high-resolution imaging combined with genetic techniques, have facilitated a better understanding of cytokine biology. We then present an overview of therapeutics arising from cytokine re-engineering, targeting and delivery, mRNA therapeutics and cell therapy. We also highlight the application of these strategies to adjust the immunological imbalance in different immune-mediated disorders, including cancer, infection and autoimmune diseases. Finally, we look ahead to the hurdles that must be overcome before cytokine therapeutics can live up to their full potential.

UR - http://www.scopus.com/inward/record.url?scp=85161576910&partnerID=8YFLogxK

U2 - 10.1038/s44222-023-00030-y

DO - 10.1038/s44222-023-00030-y

M3 - Article

C2 - 37064653

AN - SCOPUS:85161576910

SN - 2731-6092

VL - 1

SP - 286

EP - 303

JO - Nature Reviews. Bioengineering

JF - Nature Reviews. Bioengineering

IS - 4

M1 - e206

ER -

Engineering cytokine therapeutics

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Author Correction: Engineering cytokine therapeutics: Engineering cytokine therapeutics (Nature Reviews Bioengineering, (2023), 1, 4, (286-303), 10.1038/s44222-023-00030-y)

Cite this